A Phase 2A Safety and Biomarker Study of EPI-589 in Mitochondrial Subtype and Idiopathic Parkinson's Disease Subjects

Trial Profile

A Phase 2A Safety and Biomarker Study of EPI-589 in Mitochondrial Subtype and Idiopathic Parkinson's Disease Subjects

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs EPI 589 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Edison Pharmaceuticals
  • Most Recent Events

    • 19 Apr 2017 Planned End Date changed from 1 Jul 2017 to 1 Jul 2018.
    • 19 Apr 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
    • 19 Apr 2016 Planned End Date changed from 1 Apr 2017 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top